LINC02257 regulates malignant phenotypes of colorectal cancer via interacting with miR-1273g-3p and YB1
2024

LINC02257 and Its Role in Colorectal Cancer

Sample size: 482 publication 10 minutes Evidence: high

Author Information

Author(s): Park Mi-So, Jeong Seong Dong, Shin Chang Hoon, Cha Soojin, Yu Ahran, Kim Eun Ju, Gorospe Myriam, Cho Yong Beom, Won Hong-Hee, Kim Hyeon Ho

Primary Institution: Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul, Republic of Korea

Hypothesis

LINC02257 regulates malignant phenotypes of colorectal cancer via interacting with miR-1273g-3p and YB1.

Conclusion

LINC02257 is a promising therapeutic target for colorectal cancer treatment.

Supporting Evidence

  • LINC02257 is highly expressed in colorectal cancer and associated with poor survival.
  • Genome-wide association analysis revealed significant associations between variants near LINC02257 and colorectal cancer.
  • High expression levels of LINC02257 correlate with advanced tumor stages.
  • LINC02257 regulates the metastatic and proliferative potential of colorectal cancer cells.
  • LINC02257 functions as a competitive endogenous RNA for miR-1273g-3p.

Takeaway

LINC02257 is a molecule that helps cancer cells grow and spread, and blocking it could help treat colorectal cancer.

Methodology

The study used bioinformatics analyses, survival analysis, and in vitro experiments to investigate the role of LINC02257 in colorectal cancer.

Participant Demographics

The study included colorectal cancer patients from various demographics, including African American and Caucasian American populations.

Statistical Information

P-Value

0.002

Confidence Interval

1.29–3.10

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1038/s41419-024-07259-4

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication